`A2340001—29 [I,A]; 301F0015—06 [I,A]; A23L0001—33 [I,A];
`
`A2340001—326 [I,A]; 301D0021—30 [I,A]
`A2330007—005 [I,A]; A23D0007—02
`[I,A]; A23D0007—04 [I,A];
`A2340001—29 [I,A]; A23L0001—326 [I,A]; A23L0001—33 [I,A];
`
`30130021—30 [I,A]; 301F0015—06 [I,A]
`
`
`
`
`CAS INDEXING IS AVAILARLE FOR THIS PATENT.
`
`IPCR
`
`
`
`
`
`
`
`
`
`
`
`JSPATFULL on STN
`ANSWER 18 OF 27
`USPATFULL
`2006:254989
`Na:ural astaxan:hin extrac: reduces dna oxidation
`
`
`
`Chew, Boon P., Pullman, WA, UNIlED S1A_ES
`
`
`
`Park, Jean Soon, Pullman, WA, UNIlED S_A1ES
`Us 20060217445
`A1
`20060928
`Us 2004—565717
`A1
`20040726 (10)
`W0 2004—US24314
`20040726
`PCT 371 date
`20060123
`20030725 (60)
`
`Us 2003—490121P
`PRAI
`Utility
`DT
`APPEICATION
`FS
`LN.CNT 1366
`INCL
`INCEM: 514/690.000
`INCES: 514/763.000; 514/560.000
`NCEM:
`514/690.000
`
`WCES:
`514/560.000; 514/763.000
`IPCI
`A61K0031—12
`[I,A]; A61K0031—015 [I,A]
`[I,A]; A61K0031—015 [I,A]
`A61K0031—12
`IPCR
`
`
`
`CAS INDEXING IS AVAILARLE FOR THIS PATENT.
`
`
`
`
`
`
`ANSWER 19 OF 27
`2006:227598
`
`JSPATFULL on STN
`USPATFULL
`
`
`
`Preventive or remedy for arthritis
`
`Kamiya, Toshikazu,
`Ibaraki,
`JAPAN
`
`Nakagiri, Ryusuke, Chapel Hill, NC, UNIlED SlAlES
`
`
`Kyowa Hakko Kogyo Co., Ltd., Tokyo,
`JAPAN, 100—8185 (non—U.S.
`corporation)
`US 20060193962
`Us 2004—552526
`W0 2004—JP5115
`
`A1
`A1
`
`20060831
`20040409 (10)
`20040409
`20051011
`20030411
`
`PCT 371 date
`
`PRAI
`
`JP 2003—107405
`
`L4
`AN
`TI
`IN
`
`PI
`AI
`
`NCL
`
`IPC
`
`L4
`AN
`
`TI
`IN
`
`PA
`
`PI
`AI
`
`
`
`Utility
`DT
`APPEICATION
`FS
`LN.CNT 1047
`INCL
`INCEM: 426/615.000
`NCL
`NCLM:
`426/615.000
`IPC
`IPCI
`A23E0001—2l2 [I,A]
`[I,A];
`IPC?
`A2340001—212 [I,A]; A23K0001—14 [I,A]; A23K0001—16
`A2340001—30 [I,A]; A61K0031—7008 [I,A]; A61K0031—726 [I,A];
`A61<0036—00 [I,A]; A61K0036—185 [I,A]; A61P0019—02 [I,A]
`
`
`
`
`CAS INDEXING IS AVAILARLE FOR THIS PATENT.
`
`
`
`
`
`JSPATFULL on STN
`USPATFULL
`
`ANSWER 20 OF 27
`2004:209092
`
`
`
`L4
`AN
`
`TI
`IN
`
`PI
`
`AI
`
`PRAI
`
`DT
`
`Process for producing a plant extract containing plant powder
`Sa<ai, Yasushi, Tsukuba—shi,
`JAPAN
`Yo<oo, Yoshiharu, Sagamihara—shi,
`Us 20040161524
`A1
`20040819
`
`32
`US 7521079
`20090421
`US 2003—481519
`A1
`20031219 (10)
`W0 2002—JP6226
`20020621
`JP 2001—188480
`20010621
`
`JAPAN
`
`Utility
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0901
`
`page 0901
`
`

`

`
`
`APPEICATION
`FS
`LN.CNT 1479
`INCL
`INCEM: 426/655.000
`NCL
`NCEM:
`426/655.000
`
`NCES:
`426/433.000; 426/594.000; 426/597.000
`[7]
`A2340001—28 [ICM,7]
`IPCI
`IPCI—2 A2340001—28 [I,A]
`IPCR
`A2340001—28 [I,A]; A23K0001—14 [I,A]; A23K0001—16
`A2340001—30 [I,A]; A61K0036—185 [I,A]
`
`IPC
`
`L4
`AN
`TI
`
`IN
`
`PI
`AI
`
`PRAI
`
`
`
`
`
`ANSWER 21 OF 27 USPATFULL on STN
`2004:209046
`USPATFULL
`Preventives or remedies for arthritis
`
`JAPAN
`Na<agiri, Rysuke, Tokyo,
`Kamiya, Toshikazu, Tsuchiura—shi,
`Suda, Toshio, Sunto—gun,
`JAPAN
`Mi<i,
`Ichiro, Mishima—shi,
`JAPAN
`Us 20040161478
`A1
`20040819
`US 2003—480044
`A1
`20031209 (10)
`W0 2002—JP5790
`20020611
`JP 2001—181947
`20010615
`JP 2002—70702
`20020314
`
`JAPAN
`
`[I,A];
`
`
`
`Utility
`DT
`APPEICATION
`FS
`LN.CNT 1301
`INCL
`INCEM: 424/725.000
`NCL
`NCLM:
`424/725.000
`IPC
`[7]
`IPCI
`IPCR
`
`[ICM,7]
`A61K0035—78
`[I,A]; A23K0001—14 [I,A];
`[I,A]; A21D0013—08
`A21D0002—36
`[I,A]; A23L0001—30 [I,A]; A61K0036—185 [I,A];
`A23K0001—16
`A61P0019—02 [I,A]; A61P0029—00 [I,A]
`
`L4
`AN
`
`TI
`IN
`
`PI
`
`AI
`
`ANSWER 22 OF 27 USPATFULL on STN
`2004:159281
`USPATFULL
`
`
`
`
`
`Liver funcion protecting or ameliorating agent
`Sa<ai, Yasushi, Tsukuba—shi,
`JAPAN
`Kayahashi, Shun, Tsukuba—shi,
`JAPAN
`
`Hashizume, Erika, Tsukuba—shi,
`JAPAN
`Na<agiri, Ryusuke, Tokyo,
`JAPAN
`Us 20040122085
`A1
`20040624
`
`32
`US 7332522
`20080219
`Us 2003—473867
`A1
`20031003 (10)
`W0 2002—JP3098
`20020328
`
`
`
`Utility
`DT
`APPEICATION
`FS
`LN.CNT 1146
`INCL
`INCEM: 514/470.000
`NCL
`NCEM:
`514/457.000; 514/470.000
`
`NCES:
`514/470.000; 549/283.000
`[7]
`A61K0031—365 [ICM,7]
`IPCI
`IPCI—2 A61K0031—34 [I,A]; A61K0031—343 [I,A]
`IPCR
`A61K0031—34 [I,A]; A23L0001—30 [I,A]; A61K0031—343 [I,A];
`A61K0031—365 [I,A]; A61K0031—366 [I,A]; A61P0001—16 [I,A];
`C07D0307-88 [I,A]; C07D03ll—76 [I,A]
`
`ELE
`FOR THIS PAT
`
`ENT.
`CAS INDEXING IS AVAILA
`
`IPC
`
`L4
`AN
`TI
`
`
`ANSWER 23 OF 27
`USPATFULL
`2003:64375
`
` JSPATFULL on STN
`
`Processes for extracting carotenoids and for preparing feed materials
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0902
`
`page 0902
`
`

`

`
`
`ISRAE.
`<agan, Michael, Jerusalem,
`
`ISRAEL
`3raun, Sergei, Zur Hadassa,
`JS 20030044495
`A1
`20030306
`
`32
`JS 6818239
`20041116
`JS 2002—172747
`A1
`20020617 (10)
`Con:inuation of Ser. No. WO 2000—IL846, filed on 18 Dec 2000, UNKNOWN
`GB 1999—30194
`19991221
`
`
`
`
`
`
`
`
`
`
`
`J:ility
`DT
`APPEICATION
`FS
`LN.CNT 526
`INCL
`INCEM: 426/250.000
`NCL
`NCEM:
`426/429.000; 426/250.000
`
`NCES:
`426/250.000; 426/253.000; 426/43l.000; 426/478.000; 426/540.000
`[7]
`ICM,7]
`A23E0001—27
`IPCI
`ICM,7]; A23E0001—27 [ICS,7]
`IPCI—2 A23E0001—28
`I,A]; A23E0001—275 [I,A]; C07C0403—00 [I,A];
`IPCR
`A23E0001—27
`
`I,A]; C093006l—00 [I,A]
`C07C0403—24
`
`
`
`CAS INDEXING IS AVAILARLE FOR THIS PATENT.
`
`
`
`IN
`
`PI
`
`AI
`RLI
`PRAI
`
`IPC
`
`L4
`AN
`
`TI
`IN
`
`PI
`AI
`PRAI
`
`JSPATFULL on STN
`ANSWER 24 OF 27
`2002:205917 USPATFULL
`
`
`
`
`
`Liver function orotecting or improving agent
`Na<agiri, Ryusu<e, Tsukuba—shi,
`JAPAN
`Kamiya, Tosqikazu, Tsukuba—shi,
`JAPAN
`
`Hashizume, Erika, Tsukuba—shi,
`JAPAN
`Sa<ai, Yasushi,
`Inashiki—gun,
`JAPAN
`Kayahashi, Shun, Tsukuba—shi,
`JAPAN
`US 20020110605
`A1
`20020815
`us 2001—10154
`A1
`20011210 (10)
`JP 2000—375510
`20001211
`
`
`
`Utility
`DT
`APPEICATION
`FS
`LN.CNT 1786
`INCL
`INCEM: 424/725.000
`NCL
`NCLM:
`424/725.000
`TPC
`[7]
`IPCI
`IPCR
`
`[ICM,7]
`A61K0035—78
`[I,A]; A23K0001—14 [I,A];
`[I,A]; A21D0013—08
`A21D0002—36
`[I,A]; A23L0001—212 [I,A]; A23L0001—30 [I,A];
`A23K0001—16
`A61K0036—185 [I,A]; A61P0001—16 [I,A]
`
`
`
`
`CAS INDEXING IS AVAILAELE FOR THIS PATENT.
`
`
`
`JSPAT2 on STN
`USPAT2
`
`L4
`AN
`
`TI
`IN
`
`PA
`PI
`
`AI
`
`PRAI
`
`ANSWER 25 OF 27
`2004:209092
`
`
`
`Process for producing an extract of Hydrangea containing plant powder
`Sa<ai, Yasushi, Tsukuba,
`JAPAN
`JAPAN
`Yo<oo, Yoshiharu, Sagamihara,
`Kyowa Hakko Kogyo Co., Ltd., Tokyo,
`
`32
`US 7521079
`20090421
`WO 2003000074
`20030301
`US 2002—481519
`20020621 (10)
`W0 2002—JP6226
`20020621
`20031219
`20010621
`
`JAPAN (non—U.S. corporation)
`
`JP 2001—188480
`
`PCT 371 date
`
`Utili:y
`DT
`GRANTED
`FS
`LN.CNT 1371
`INCL
`INCEM: 426/655.000
`INCES: 426/594.000; 426/597.000; 426/433.000
`NCEM:
`426/655.000
`
`NCES:
`426/433.000; 426/594.000; 426/597.000
`
`NCL
`
`
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0903
`
`page 0903
`
`

`

`IPC
`
`
`
`AN
`
`PA
`PI
`
`AI
`
`PRAI
`DT
`FS
`LN.CNT
`INCL
`
`NCL
`
`IPC
`
`EXF
`CAS
`
`
`
`AN
`TI
`IN
`
`AN
`
`PA
`PI
`AI
`RLI
`PRAI
`DT
`FS
`LN.CNT
`INCL
`
`NCL
`
`IPC
`
`A23K0001—14
`A61K0036—l85
`
`[I,A]; A23K0001—l6
`[I,A]
`
`[LA];
`
`[ [
`
`ICM, 7]
`A]
`I
`[I
`A].
`[LA];
`26/594
`
`4
`
`30001—28
`A23
`IPCI
`IPCI—2 A23
`30001—28
`IPCR
`A2330001—28
`A2330001—30
`
`
`
`426/597; 426/433;
`
`SWER 26 OF 27
`2004:159281
`
`USPAT2 on STN
`USPAT2
`
`
`
`Liver function protecting or ameliorating agent
`Tsu
`JAPAN
`kuba,
`Sa<ai,
`Yasushi,
`is
`JAPAN
`Shun,
`ukuba,
`Kayahashi,
`T
`
`JAPAN
`sukuba,
`Hashizume, Erika,
`JAPAN
`Tokyo,
`Na<agiri, Ryusuke,
`0. Ltd.,
`Kyowa Hakko Kogyo C
`Tokyo,
`32
`US 7332522
`20080219
`WO 2002080904
`20021017
`US 2002—473867
`20020328
`WO 2002—JP3098
`20020328
`20031003
`20010405
`
`JAPAN (non—U.S. corporation)
`
`(10)
`
`PCT 371 date
`
`JP 2001—106600
`
`
`
`
`
`Utili:y
`
`GRANTED
`1099
`INC4M:
`INC4S:
`NC4M:
`
`NCuS:
`IPCI
`IPCI—2
`IPCR
`
`000
`514/457.
`514/470.
`000;
`514/457.000;
`514/470.000;
`A61K003l—365
`A61K003l—34
`A61K003l—34
`A61K003l—365
`C07D0307— 88
`5..|
`549/283, 549/290;
`
`*.
`
`IND
`
`EXING IS AVAIT.A%T.
`
`
`
`549/283.000
`514/470.000
`549/283.000
`[ICM,7]
`A61K003l—343
`[I,A]
`[LA];
`A61K003l—343
`A23L0001—30
`[LA];
`[LA];
`A61K003l—366
`A61P0001—l6
`[LA];
`[LA];
`C07D0311—76
`[LA];
`[I,A]
`549/289;
`49/307;
`514/457;
`
`ENT.
`FOR THIS PAT
`
`514/470
`
`[LA];
`[LA];
`
`(non—U.S. corporation)
`
`No.
`
`filed on 18 Dec 2000
`
`
`SWER 27 OF 27
`JSPAT2 on STN
`2003:64375 USPAT2
`Processes for extra
`_‘4
`cting carote
`noids and for preparing feed materials
`
`ISRA.
`_‘4
`Jerusalem,
`<agan, Michael,
`
`ISRA.
`_‘4
`Zur Hadassa,
`3raun, Sergei,
`
`ISRA..
`Fermeqtron Ltd.,
`Jerusalem,
`32
`JS 6818239
`20041116
`JS 2002—172747
`20020617
`(10)
`Con:i
`duation of Ser.
`WO 2000—IL846,
`GB 1999—30194
`19991221
`
`4 4
`
`
`
`EXF
`
`426/807; 426/250;
`-—u
`426/478; 426/540;
`
`*.
`
`
`
`CAS IND
`EXING IS AVAILA3L
`
`426/478.000;
`426/250.000
`426/253.000;
`
`426/250.000; 426/253.000; 426/540.000
`
`426/431.000; 426/478.000; 426/540.000
`
`[ [ [
`
`ICM, 7]
`A23L0001—27
`ICM, 7];
`30001—275
`I
`A]; A23
`
`30061—00
`[1,A]; C09
`26/253;
`426/635;
`424/451
`24/439;
`
`ENT.
`FOR THIS PAT
`
`[ICS,7]
`[I,A]; C07C0403—00
`[IIA]
`426/425;
`
`[LA];
`
`426/429; 426/430; 426/431;
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0904
`
`page 0904
`
`426/429.
`426/431.
`426/429.
`426/250.
`
`000
`000;
`000;
`000;
`
`A2330001—27
`A2330001—28
`A2330001—27
`C07C0403—24
`
`
`
`
`
`J G 5 I
`
`
`
`
`
`
`
`WC_4M:
`IWC4S:
`NC4M:
`
`NCuS:
`[7]
`IPCI
`IPCI—2
`IPCR
`
`:ili:y
`RAVTED
`
`

`

`=> d his:
`
`
`
`
`
`
`(bI.E 'HO E' ENTERED A1 15:15:33 ON 03 JAN 2012)
`
`
`
`
`INDEX 'ADISCTI, ADISINSIGIT, ADISNEWS, AGRICOEA, ANA3STR, ANTE, AQUA.INE,
`
`
`
`
`
`
`AQUASCI, EIOENG, EIOSIS, EIOTECHAES, EIO.EC{DS, EIOTECHNO, CA3A, CAPEUS,
`
`
`
`
`
`
`CEAEA—VTE, CIN, CONFSCI, CROP3, CROPU, DDb3, DDbJ, DGENE, DISSA3S, DRUGB,
`
`
`
`
`
`DRUGU, E EAL, EMEASE, ESEIOEASE,
`...' EN.ERED A1 15:15:4
`ON 03 JAN 2012
`
`
`
`
`SEA KRIL. AND OIE AND
`EAL AND SJPERCRITICAL(P)EXTRACT? AND SOL
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`0* FI.E ADISNEWS
`
`bI.E ANIE
`0*
`
`0* FI.E AQUA.INE
`
`bI.E EIOENG
`0*
`
`
`bI.E EIO_ECHAES
`0*
`
`bI.E EIO_ECHDS
`0*
`0*
`bI.E EIO_ECHNO
`
`
`bI.E CEAEA—VIR
`0*
`
`0* FI.E CIN
`0* FI.E FOMAD
`
`0* FI.E FROSTI
`
`0* FI.E FSTA
`
`
` bI.E IbIPA.
`1
`
`
`
`bI.E KOSME.
`0*
`
`0* FI.E NTIS
`
`
`0* FI.E PASCAL
`
`
`bI.E USPA_bULL
`28
`
`
`bI.E USPA_2
`4
`
`bI.E WATER
`0*
`1
`FI.E WPIDS
`
`1
`FI.E WPINDEX
`
`
`
`
`QUE KRILL AND OIL AND EA. AND SUPERCRITICAL(P)EXTRACT? AND SOL
`
`
`
`
`
`L1
`
`E2
`E3
`E4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`FILE 'IFIPAT, USPATFULE, USPA12' ENIERED A1 15:19:01 ON 03 JAN 2012
`33 S E1
`
`
`
`(1 DJPLICAIE REMOVED)
`32 DUP REM L2
`
`27 S E3 AND DIOXIDE
`
`
`
`
`=> "ogoff
`
`
`
`
`
`
`
`ALL L# QUERIES AND ANSWER SEIS ARE DELETED A1 LOGObh
`LOGOFF?
`(Y)/N/HOED:y
`COST IN U.S. DOLEARS
`
`
`bULL ESIIMA.ED COSI
`
`
`SIN INIERNA.IONAL LOGOFF AT 15:21:58 ON 03 JAN 2012
`
`
`
`
`
`
`
`SINCE bILE
`
`ENTRY
`43.57
`
`TOTAL
`
`SESSION
`47.51
`
`RIMFRO ST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0905
`
`page 0905
`
`

`

`WEST Search History for Application 12057775
`
`Creation Date: 2012010315:00
`
`Prior Art Searches
`
`—-:-m
`
`Thes.
`
`Date
`
`"krill oil"
`
`YES
`
`01—03-2012
`
`PGPB, USPT, USOC,
`EPAB, JPAB, DWPI,
`TDBD
`
`PGPB, USPT, USOC,
`EPAB, JPAB, DWPI,
`TDBD
`
`("krill oil" ) and "krill meal"
`
`01—03-2012
`
`("krill oil" and "krill meal" ) and
`
`PGPB, USPT, USOC,
`
`01—03-2012
`
`"supercritical fluid"
`
`EPAB, JPAB, DWPI,
`TDBD
`
`extract? and krill and oil and meal and
`
`PGPB, USPT, USOC,
`
`01—03-2012
`
`supercritical
`
`EPAB, JPAB, DWPI,
`TDBD
`
`01—03-2012
`
`Im{/1
`t-<m{/2
`
`01—03-2012
`
`01—03-2012
`
`t-<m{/2
`
`01—03-2012
`
`Im{/1
`t-<m{/2
`
`t-<m{/2
`
`Im(I)
`m{/1
`
`01—03-2012
`
`01—03-2012
`
`01—03-2012
`
`01-03-2012
`
`01—03-2012
`
`01—03-2012
`
`01—03-2012
`
`(20040241249) and "supercritical"
`
`(20040241249 ) and "solvent extraction"
`
`(20040241249 ) and "extract"
`
`(20040241249 and "extract" ) and "oil"
`
`(20040241249 and "extract" and "oil" )
`and "meal"
`
`supercritical and extraction and krill
`
`(supercritical and extraction and krill)
`and co-solvent
`
`(supercritical and extraction and krill
`and co-solvent ) and oil
`
`PGPB
`
`PGPB
`
`PGPB
`
`PGPB
`
`PGPB, USPT, USOC,
`EPAB, JPAB, DWPI,
`TDBD
`
`PGPB, USPT, USOC,
`EPAB, JPAB, DWPI,
`TDBD
`
`PGPB, USPT, USOC,
`EPAB, JPAB, DWPI,
`TDBD
`
`supercritical and extraction and alcohol
`
`01-03-2012
`
`WEST Search History for Application 12057775
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0906
`
`1
`page 0906
`
`

`

`PGPB, USPT, USOC,
`EPAB, JPAB, DWPI,
`TDBD
`
`(supercritical and extraction and alcohol
`
`PGPB, USPT, USOC,
`
`YES
`
`01-03-2012
`
`TDBD 01—03-2012
`
`fill
`
`) and monohydric
`
`EPAB, JPAB, DWPI,
`TDBD
`
`(supercritical and extraction and alcohol
`
`PGPB, USPT, USOC,
`
`and monohydric ) and krill and meal
`
`EPAB, JPAB, DWPI,
`
`Prior Art Searches
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0907
`
`2
`page 0907
`
`

`

`12057775 ~ dissipate)
`figggjgttggate: 03/08/2011
`Approved for use through 078112012. OMB 0651-0031
`Doc description: Information Disclosure Statement (IDS) Filed
`US. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`12057775
`2008-03-28
`Filing Date
`
`First Named Inventor
`Inge Bruheim, et al.
`I 1651
`Susan Marie Hanley
`| NATNUT-14409/US-5/ORD
`
`Art Unit
`
`Examiner Name
`
` Attorney Docket Number
`
`
`
`
`
`U.S.PATENTS
`_
`
`.
`.
`Examiner C'te
`Initial
`No
`
`Patent Number
`
`.
`Kmd
`Code1
`
`Issue Date
`
`.
`Pages,Columns,Lines where
`Name Of Patentee or Applicant Relevant Passages or Relevant
`of Cited Document
`.
`Figures Appear
`
`1
`
`
`
`
`If you wish to add additional US. Patent citation information please click the Add button.
`
`Add
`
`
`
`U.S.PATENT APPLICATION PUBLICATIONS
`_—
`
`Examiner
`.
`.
`*
`Initial
`
`Cite No
`
`Publication
`Number
`
`Publication
`Kind
`Code1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.-
`
`FOREIGN PATENT DOCUMENTS
`_
`
`Pages,Columns,Lines
`Name of Patentee or
`where Relevant
`A licant of cited
`Publication
`Kind
`Country
`Examiner Cite Foreign Document
`Initial*
`No
`Number3
`Code2 i
`Code4 Date
`pp
`Passages or Relevant
`Document
`.
`
`Figures Appear
`
`NIPPON SUISAN
`1
`2000/25608
`WO
`2000-05-11
`KAISHA, LTD.
`El
`
`
`
`
`
`
`
`
`
`
`
`
`
`D
`méA'RSON MED'CAL
`2000-07-06
`wo
`2000138708
`2
`
`
`3
`
`2002/102394
`
`WO
`
`NEPTUNE
`
`2002-12-27
`
`TECHNOLOGIES &
`BIORESS
`
`|:|
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXQHWWSEEEEIWWR®Q§QQO$UWJ
`
`RIMFROST EXHIBIT 1024 page 0908
`
`

`

`
`
`Receipt date: 03/08/2011
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`
`12057775 12057775 ~ GAL}: 1651
`Application Number
`2008-03-28
`Filing Date
`Inge Bruheim, et al.
`First Named Inventor
`
`Art Unit
`
`Susan Marie Hanley Attorney Docket Number
`I 1651
`
`Examiner Name
`| NATNUT-14409/US-5/ORD
`
`2003/01 1873
`
`WO
`
`2003-02-13
`
`NEPTUNE
`TECHNOLOGIES &
`BIORESSOURCES INC.
`
`2005/004393
`
`WO
`
`2005/037848
`
`WO
`
`2005/038037
`
`WO
`
`2007/080514
`
`WO
`
`
`
`
`
`
`
`2005-01-13
`
`KONIN-KLIJKE PHILIPS
`ELECTRONICS NV.
`
`2005-04-28
`
`ENZYMOTEC LTD.
`
`2005-04-28
`
`ENZYMOTEC INC.
`
`2007-07-19
`
`KRILL A/S
`
`
`
`
`
`
`
`
`2007/080515
`
`WC
`
`2007-07-19
`
`AKER BIOMARINE ASA
`
`2007/ 1 08702
`
`2007-09-27
`
`AKER SEAFOODS
`HOLDING AS
`
`2008/006607
`
`2008-01-17
`
`NA'I‘I'OPHARMA ASA
`
`2008/1 1 7062
`
`2008-10-02
`
`AKER BIOMARINE ASA
`
`2009/027692
`
`2009-03-05
`
`AKER BIOMARINE ASA
`
`2001/028526
`
`2001 -04-26
`
`TRUFFINI & REGGE
`FARMACEUTICI
`
`EFS Web 2.1.17
`
`ALI. REFERENCES CONSIDERED EXQHMFWSEEEEIWGMR®Q§QQO9UWJ
`
`RIMFROST EXHIBIT 1024 page 0909
`
`
`
`

`

`
`
`Receipt date: 03/08/2011
`
`INFORMATION DISCLOSURE
`
`
`
`12057775 12057775 ~ GAL): 1651
`Application Number
`2008-03-28
`Filing Date
`Inge Bruheim, et al.
`First Named Inventor
`
`STATEMENT BY APPLICANT
`
`Art Unit
`
`( Not for submission under 37 CFR 1.99)
`
`Examiner Name
`| NATNUT-14409/US-5/ORD
`
`Susan Marie Hanley Attorney Docket Number
`I 1651
`
`
`
`
`
`
`
`
`
`|.B.R ISRAELI
`BIOTECHNOLOGY
`RESEARCH LTD.
`
`UNIVERSITE DE
`SHERBROOKE
`
`ACCERA, INC.
`
`HENDERSON
`
`SUNTORY LIMITED
`
`NEPTUNE
`TECHNOLOGIES &
`BIORESSOURCES, INC.
`
`YEDA RESEARCH AND
`DEVELOPMENT CO.
`LTD
`
`YEDA RESEARCH AND
`DEVELOPMENT CO.
`LTD
`
`MARTEK BIOSCIENCES
`BOULDER
`CORPORATION
`
`MARTEK BIOSCIENCES
`BOULDER
`CORPORATION
`
`
`
`
`
`2004/047554
`
`2004-06-10
`
`PHARES PHARM RES
`NV
`
`16
`
`17
`
`18
`
`0973532
`
`1 123368
`
`1292294
`
`EP
`
`EP
`
`EP
`
`2005-09-07
`
`2008-04-09
`
`2009-03-18
`
`20011082928
`
`2001-11-08
`
`
`
`20031013497
`
`
`
`1419788
`
`1385500
`
`EP
`
`EP
`
`2002/083122
`
`21
`
`22
`
`24
`
`2003-02-20
`
`2009-01-07
`
`2010-07-28
`
`2002-10-24
`
`1392623
`
`2004-03-03
`
`2002/092540
`
`2002-1 1 -21
`
`EFS Web 2.1.17
`
`ALI. REFERENCES CONSIDERED EXQHWWSEEEEIWWR®Q§QQWUWJ
`
`RIMFROST EXHIBIT 1024 page 0910
`
`

`

`
`
`12057775 12057775 ~ GAL}: 1651
`Application Number
`2008-03-28
`Filing Date
`Inge Bruheim, et al.
`First Named Inventor
`I 1651
`Art Unit
`Examiner Name
`| NATNUT-14409/US-5/ORD
`
`Receipt date: 03/08/2011
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`20061030552
`
`
`
`
` Susan Marie Hanley Attorney Docket Number
`
`
`
`26
`
`1406641
`
`EP
`
`2005/07041 1
`
`28
`
`1542670
`
`EP
`
`20041028529
`
`
`
`30
`
`1743531
`
`31
`
`1631280
`
`EP
`
`EP
`
` 2004/100943
`
`33
`
`1660071
`
`EP
`
`20051018632
`
`36
`
`1689413
`
`EP
`
`2009-01-07
`
`NEPTUNE
`TECHNOLOGIES &
`BIORESSOURCES, INC.
`
`2005-08-04
`
`BRUZZESE
`
`2005-06-22
`
`SUNTORY LIMITED
`
`Identical to
`W02004028529
`
`2006-08-16
`
`
`
`2004-04-08
`
`SUNTORY LIMITED
`
`2007-01-17
`
`NIPPON SUISAN
`KAISHA, LTD
`
`2008-03-08
`
`BTG INTERNATIONAL
`LIMITED
`
`2004-1 1 -25
`
`BTG INTERNATIONAL
`LIMITED
`
`2006-05-31
`
`BTG INTERNATIONAL
`LIMITED
`
`2005-03-03
`
`BTG INTERNATIONAL
`LIMITED
`
`2006-03-23
`
`SUNTORY LIMITED
`
`ENZYMOTEC LTD.
`
`EFS Web 2.1.17
`
`ALI. REFERENCES CONSIDERED EXQHWWSEEEEIWWR®Q§QQHUWJ
`
`RIMFROST EXHIBIT 1024 page 0911
`
`

`

`
`
`Receipt date: 03/08/2011
`
`
`Application Number
`12057775
`12057775 ~ GAL): 1651
`
`Filing Date
`2008-03-28
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`First Named Inventor
`Inge Bruheim, etal.
`
`Art Unit
`| 1651
`Examiner Name
`Susan Marie Hanley
`
`I NATNUT-14409/US-5/ORD
`
` Attorney Docket Number
`
`37
`1706106 I.20090715
`BRUZZESE _
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`NON-PATENT LITERATURE DOCUMENTS
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`T5
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`
`publisher, city and/or country where published.
`
`Examiner Cite
`
`1
`
`|:|
`
`
`
`
`
`
`
`TAKAICHI et al., 2003, “Fatty Acids of astaxanthin esters in krill determined by mild mass spectrometry", Comparative
`Biochemistry and Physiology Part B, Biochemistry and Molecular Biology, Elsevier, Oxford, Vol. 136, 1 January 2003,
`p. 317-322;
`
`
`El
`TANAKA et al., 2004, “Extraction of Phospholipids from Salmon Roe with Supercritical Carbon Dioxide and an
`2
`Entrainer”, J. Oleo Sci, 53(9): 417—424
`
`
`El
`TANAKA et al., 2005, “Extraction of Phospholipids from Unused Natrual Resources with Supercritical Carbon Dioxide
`3
`and an Entrainer", Journal of Oleo Science, Vol. 54(11): 569—576
`
`
`El
`TODORIC et al., 2006, “Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by
`4
`n—3 polyunsaturated fatty acids”, Diabetologia, 49(9): 2109—21 19
`
`
`TOU et al., 2007, “Krill for human consumption: nutritional value and potential health benefits", Nutrition Rev 65
`_
`(2)63—77
`
`
`5
`
`D
`
`El
`TRAYHURN et al., 2004, “Adipokines: inflammation and the pleiotropic role of white adipose tissue", Br. J. Nutrition,
`6
`92(3): 347—355
`
`
`TREBBLE et al., 2003, “Inhibition of tumour necrosis factor—alpha and interleukin 6 production by mononuclear cells
`following dietary fish-oil supplementation in healthy men and response to antioxidant co—supplementation”, Br. J.
`Nutrition, 90(2): 405-412
`
`
`7
`
`|:|
`
`El
`UKKOLA et al., 2002, “Adiponectin: a link between excess adiposity and associated comorbidities?", J. Mol. Med, 80
`(11): 696—702
`
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSiDERED EXQHMFWSEEEEIBEEDWR®MQQIZDWJ
`
`RIMFROST EXHIBIT 1024 page 0912
`
`

`

`
`
`Receipt date: 03/08/2011
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Application Number
`12057775
`12057775 ~ GAL): 1651
`
`Filing Date
`2008-03-28
`
`
`First Named Inventor
`Inge Bruheim, etal.
`Art Unit
`| 1651
`Examiner Name
`Susan Marie Hanley
`Attorney Docket Number
`I NATNUT-144091US-510RD
`
`
`
`
`
`
`
`
`VAN DER VEEN et al., 1971 "The Lipids of Krill (Euphausia Species) and Red Crab (Pleuroncodes Planipes)”, Lipids,
`6(7): 481-485
`
`VIRTUE, et al. 1996, Reproductive trade—off in male Antarctic krill, Euphausla superba", Marine Biology, Volume 126,
`Number 3, Pages 521-527
`
`YAMAGUCHI et al., 1983, “The Composition of Carotenoid Pigments in the Antarctic Krill Euphausia superba”, Bulletin
`of the Japanese Society of Scientific Fisheries, 49(9): 1411-1415
`
`YAMAGUCHI et al., 1986, “Supercritical Carbon Dioxide Extraction Of Oils From Antarctic Krill,” Journal Of Agricultural
`And Food Chemistry, vol. 34, pp. 904-907
`
`YANASE M; 1974, “Modification of a Russian method for separation of heat-coagulated protein from Antarctic krill”,
`Database FSTA (online); International Food Information Service (IFIS); FRANKFURT—MAIN, DE
`
`YEN et al., 1994, “Effect of dietary omega-3 and omega-6 fatty acid sources on PUVA-induced cutaneous toxicity and
`tumorogenesis in the hairless mouse", Arch. Dermatol. Res, 286(6): 331-6
`
`DATABASE WPI Week 200682, Thomson Scientific, London, GB, 2006
`
`ENGLISH ABSTRACT; JP 2003-531857; See abstract from corresponding WO 20011082928 filed herewith
`
`ENGLISH ABSTRACT; JP 21304-525180; See abstract from corresponding WO 20021083122 filed herewith
`
`ENGLISH ABSTRACT; JP 2006-528233; See abstract from corresponding WO 20041100943 filed herewith
`
`ENGLISH ABSTRACT; JP 21307-502805; See abstract from corresponding WO 20051018632 filed herewith
`
`EFSWeb2.1.17
`
`ALI. REFERENCES CONStDERED EXQHMFWSEEEEIBEHDWR®MQQUDWJ
`
`RIMFROST EXHIBIT 1024 page 0913
`
`

`

`
`
`Receipt date: 03/08/2011
`
`
`Application Number
`12057775
`12057775 ~ GAL): 1851
`
`Filing Date
`2008-03-28
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`First Named Inventor
`Inge Bruheim, etal.
`Art Unit
`| 1651
`Examiner Name
`Susan Marie Hanley
`Attorney Docket Number
`I NATNUT-14409/US-510RD
`
`
`
`
`
`
`
`
`
`ENGLISH ABSTRACT; JP 2007-509131; See abstract from corresponding WO 20051037848 filed herewith
`
`ENGLISH ABSTRACT; JP 2007-518764; See abstract from corresponding WO 20051070411 filed herewith
`
`ENGLISH ABSTRACT; JP 2004-536059; See abstract from corresponding WO 2002109254 filed herewith
`
`ENGLISH ABSTRACT; JP 20065-502196; See abstract from corresponding WO 20041028529 filed herewith
`
`If you wish to add additional non-patent literature document citation information please click the Add button
`
`EXAMINER SIGNATURE
`
`Examiner Signature
`
`
`19900130 Ware!
`Date Considered
`
`1 2 [/3 Q /1 1
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`2 Enter office that issued the document, by the two-letter code (WIPO
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04.
`Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
`5 Applicant is to place a check mark here if
`English language translation is attached.
`
`EFSWeb2.1.17
`
`ALI. REFERENCES SONStDERED EXQHMFWSEEEEIBEHDWR®MQQMDWJ
`
`RIMFROST EXHIBIT 1024 page 0914
`
`

`

`
`
`Application/Control No.
`
`Search NOTES
`
`12057775
`
`Applicant(s)/Patent Under
`Reexamination
`
`BRUHEIM ET AL.
`
`
`
`
`
`
`Examiner
`
`DEBBIE K WARE
`
`Art Unit
`
`1651
`
`SEARCHED
`
`SEARCH NOTES
`
`INTERFERENCE SEARCH
`
`Search Notes
`WEST, NPL and INV: see search history print out
`
`mum
`12/2011-1/2012
`
`
`
`US. Patent and Trademark Office
`
`RIMFRO ST EXHIBI’TT &%4 NO. WMIS
`
`RIMFROST EXHIBIT 1024 page 0915
`
`

`

`Index Of Claims
`
`12057775
`
`BRUHEIM ET AL.
`
`Application/Control No.
`
`Applicant(s)/Patent Under
`Reexamination
`
`Examiner
`
`DEBBIE K WARE
`
`Art Unit
`
`1651
`
`
`
`Rejected I Cancelled n Non-Elected n Appeal
`a Allowed a Restricted _ [In Objected
`
`I] Claims renumbered in the same order as presented by applicant
`
`I] O 'U>
`
`_| U
`
`I] R.1.47
`
`CLAIM
`
`DATE
`
`Final __________
`——--------
`__—_______
`__—_______
`__—_______
`__—_______
`n—————————
`__—_______
`n—————————
`n—————————
`__—_______
`__—_______
`12 —--------
`13 ________
`
`N _L
`NN
`
`“344444.;OCOOOVO‘JU‘I-h
`00N—lO00
`NNNNNN(OOOVO‘JU‘l-h
`
`
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.. 20111230
`
`22
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0916
`
`page 0916
`
`

`

`Index Of Claims
`
`12057775
`
`BRUHEIM ET AL.
`
`Application/Control No.
`
`Applicant(s)/Patent Under
`Reexamination
`
`Examiner
`
`DEBBIE K WARE
`
`Art Unit
`
`1651
`
`
`
`Rejected I Cancelled n Non-Elected n Appeal
`a Allowed a Restricted _ [In Objected
`
`I] Claims renumbered in the same order as presented by applicant
`
`I] O 'U>
`
`_| U
`
`I] R.1.47
`
`
`
`CLAIM
`
`DATE
`
`Final __________
`_—________
`_—________
`_—________
`_—________
`41 —--------
`42 —--------
`43 —--------
`44 —--------
`45 —--------
`46 —--------
`47 —--------
`48 —--------
`49 —--------
`01O
`— \/
`
`01010101th—l
`
`0101
`
`010101COMO)
`
`01O
`
`0303N—l
`O)00
`
`030301%
`
`VEHH\l
`
`H
`
`22
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.. 20111230
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0917
`
`page 0917
`
`

`

`Index Of Claims
`
`12057775
`
`BRUHEIM ET AL.
`
`Application/Control No.
`
`Applicant(s)/Patent Under
`Reexamination
`
`Examiner
`
`DEBBIE K WARE
`
`Art Unit
`
`1651
`
`I] Claims renumbered in the same order as presented by applicant
`
`I] CPA
`
`T.D.
`
`
`
`
`Rejected I Cancelled n Non-Elected n Appeal
`a Allowed a Restricted _ [In Objected
`
`I]
`
`R. 1. 47
`
`CLAIM
`
`Final __________
`_—________
`——--------
`——--------
`——--------
`__—_______
`__—_______
`__—_______
`“—________
`__—_______
`__—_______
`__—_______
`__—_______
`__—_______
`“—________
`__—_______
`__—_______
`n—________
`“—________
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.
`
`: 20111230
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0918
`
`page 0918
`
`

`

`Attorney Docket No.: NATNUT-14409/US-5/ORD
`
`PA TENT
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Application of: Bruheim et al.
`Serial No.:
`12/057,775
`
`Art Unit: 1651
`Examiner: Ware
`
`Filed:
`Entitled:
`
`Confirmation: 1945
`March 28, 2008
`BIOEFFECTIVE KRIL OIL COMPOSITIONS
`
`RESPONSE TO RESTRICTION REQUIREMENT
`
`MAILED SEPTEMBER 8, 2011
`
`EFS WEB FILED
`
`Commissioner for Patents
`
`PO. Box 1450
`
`Alexandria, Virginia 22313-1450
`
`Examiner Ware:
`
`This communication is responsive to the Office Action mailed September 8, 2011. The
`
`Commissioner is hereby authorized to charge any fees during the entire pendency of this
`
`application, including fees due under 37 CPR. §§ 1.16 and 1.17 that may be required, including
`
`any required extension of time fees, or credit any overpayment to Deposit Account 50-4302,
`
`referencing Attorney Docket No. NATNUT-14409/US-5/ORD. This paragraph is intended to
`
`be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 CPR.
`
`§ 1.136(a)(3).
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0919
`
`page 0919
`
`

`

`Attorney Docket No.: NATNUT-14409/US-5/0RD
`
`PA TENT
`
`IN THE CLAIMS
`
`1.
`
`(Withdrawn) A composition comprising:
`
`from about 3% to 10% ether phospholipids on a w/w basis;
`
`from about 35% to 50% non-ether phospholipids on w/w basis, so that the total amount of
`
`ether phospholipids and non-ether phospholipids in the composition is from about 48% to 60%
`
`on a w/w basis;
`
`from about 20% to 45% triglycerides on a w/w basis;
`
`and from about 400 to about 2500 mg/kg astaxanthin.
`
`2.
`
`(Withdrawn) The composition of Claim 1, wherein said ether phospholipids are selected
`
`from the group consisting of alkylacylphosphatidylcholine, lyso-alkylacylphosphatidylcholine,
`
`alkylacylphosphatidylethanolamine, and combinations thereof.
`
`3.
`
`(Withdrawn) The composition of Claim 1, wherein said ether lipids are greater than 90%
`
`alkylacylphosphatidylcholine.
`
`4.
`
`(Withdrawn) The composition of Claim 1, wherein said non-ether phospholipids are
`
`selected from the group consisting of phosphatidylcholine, phosphatidylserine,
`
`phosphatidylethanolamine and combinations thereof.
`
`5.
`
`(Withdrawn) The composition of Claim 1, wherein said composition comprises a blend
`
`of lipid fractions obtained from Euphausz'a superba.
`
`6.
`
`(Withdrawn) The composition of Claim 1, wherein said composition comprises from
`
`about 25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from
`
`about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids.
`
`7.
`
`(Withdrawn) A capsule containing the composition of Claim 1.
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0920
`
`page 0920
`
`

`

`Attorney Docket No.: NATNUT-14409/US-5/0RD
`
`PA TENT
`
`8.
`
`(Withdrawn) A composition comprising:
`
`from about 3% to 10% ether phospholipids on a w/w basis; and
`
`from about 400 to about 2500 mg/kg astaxanthin.
`
`9.
`
`(Withdrawn) The composition of Claim 8, further comprising from about 35% to 50%
`
`non-ether phospholipids on w/w basis, so that the total amount of ether phospholipids and non-
`
`ether phospholipids in the composition is from about 38% to 60% on a w/w basis.
`
`10.
`
`(Withdrawn) The composition of Claim 8, further comprising from about 20% to 45%
`
`triglycerides on a w/w basis.
`
`ll.
`
`(Withdrawn) The composition of Claim 8, wherein said ether phospholipids are selected
`
`from the group consisting of alkylacylphosphatidylcholine, lyso-alkylacylphosphatidylcholine,
`
`alkylacylphosphatidylethanolamine, and combinations thereof.
`
`12.
`
`(Withdrawn) The composition of Claim ll, wherein said ether lipids are greater than
`
`90% alkylacylphosphatidylcholine.
`
`l3.
`
`(Withdrawn) The composition of Claim 8, wherein said non-ether phospholipids are
`
`selected from the group consisting of phosphatidylcholine, phosphatidylserine,
`
`phosphatidylethanolamine and combinations thereof.
`
`14.
`
`(Withdrawn) The composition of Claim 8, wherein said composition comprises a blend
`
`of lipid fractions obtained from Euphausz'a superba.
`
`l5.
`
`(Withdrawn) The composition of Claim 10, wherein said composition comprises from
`
`about 25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from
`
`about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids.
`
`l6.
`
`(Withdrawn) A capsule containing the composition of Claim 8.
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0921
`
`page 0921
`
`

`

`Attorney Docket No.: NATNUT-14409/US-5/ORD
`
`PA TENT
`
`l7.
`
`(Withdrawn) A blended krill oil composition comprising:
`
`from about 45% to 55% w/w phospholipids;
`
`from about 20% to 45% w/w triglycerides;
`
`and from about 400 to about 2500 mg/kg astaxanthin.
`
`18.
`
`(Withdrawn) The composition of Claim 17, wherein said blended krill oil product
`
`comprises a blend of lipid fractions obtained from Euphausz’a superba.
`
`l9.
`
`(Withdrawn) The composition of Claim 17, wherein said composition comprises from
`
`about 25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from
`
`about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids.
`
`20.
`
`(Withdrawn) A Euphausz'a superba krill oil composition comprising:
`
`from about 3% to about 10% w/w ether phospholipids;
`
`from about 27% to 50% w/w non-ether phospholipids so that the amount of total
`
`phospholipids in the composition is from about 30% to 60% w/w;
`
`from about 20% to 50% w/w triglycerides;
`
`from about 400 to about 25 00 mg/kg astaxanthin; and
`
`from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said
`
`composition, wherein from about 70% to 95% of said omega-3 fatty acids are attached to said
`
`phospholipids.
`
`2l.
`
`(Withdrawn) A dietary supplement comprising encapsulated Euphausz'a superba krill oil
`
`comprising from about 3% to about 10% w/w ether phospholipids; from about 27% to 50% w/w
`
`non-ether phospholipids so that the amount of total phospholipids in the composition is from
`
`about 30% to 60% w/w; from about 20% to 50% w/w triglycerides; from about 400 to about
`
`2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of
`
`total fatty acids in said composition, wherein from about 70% to 95% of said omega-3 fatty acids
`
`are attached to said phospholipids.
`
`RIMFROST EXHIBIT 1024
`
`RIMFROST EXHIBIT 1024 page 0922
`
`page 0922
`
`

`

`Attorney Docket No.: NATNUT-14409/US-5/ORD
`
`PA TENT
`
`22.
`
`(Withdrawn) A method of making a Euphausz‘a superba krill oil composition comprising:
`
`contacting Euphausz'a superba with a polar solvent to provide a polar extract comprising
`
`phospholipids;
`
`contacting Euphasia superba with a neutral solvent
`
`to provide a neutral extract
`
`comprising triglycerides and astaxanthin;
`
`combining said polar extract and said neutral extract to provide Euphausz'a superba krill
`
`oil from about 3% to about 10% w/w ether phospholipids; from about 27% to 50% w/w non-
`
`ether phospholipids so that the amount of total phospholipids in the composition is from about
`
`30% to 60% w/w; from about 20% to 50%